AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20678132 — intervention group
Group type: COMPARATOR
Intervention: Immediately placed implants in sockets with periapical pathologies (control group)
Number of subjects: 29
Study 20678132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 29
Study 19321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality cognitive behavior therapy (VRCBT)
Number of subjects: 88
Study 19321811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 88
Study 19321811 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 88
Study 17003842 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in the vasoactive intestinal peptide (VIP) gene
Number of subjects: 10
Study 17003842 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in the noncoding regions of the VIP gene
Number of subjects: 10
Study 17003842 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in the coding regions of the VIP gene
Number of subjects: 10
Study 17003842 — intervention group
Group type: COMPARATOR
Intervention: VIP gene alterations correlation with IPAH
Number of subjects: 10
Study 14704545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined viscocanalostomy and cataract surgery (VCS group)
Number of subjects: 206
Study 14704545 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone (CSA group)
Number of subjects: 206
Study 11309007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and adrenaline infiltration
Number of subjects: 8
Study 11309007 — intervention group
Group type: COMPARATOR
Intervention: Saline and adrenaline infiltration (Control)
Number of subjects: 8
Study 9656847 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS-free dentifrice
Number of subjects: 0
Study 9656847 — intervention group
Group type: COMPARATOR
Intervention: SLS-containing dentifrice
Number of subjects: 0
Study 7701262 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0
Study 7701262 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 0
Study 3668124 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-mixed grass-pollen allergoid
Number of subjects: 45
Study 3668124 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized orchard grass-pollen extract
Number of subjects: 45
Study 3668124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30124753 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg daily, orally)
Number of subjects: 0
Study 30124753 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine)
Number of subjects: 0
Study 27799176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg i.v. paracetamol
Number of subjects: 80
Study 27799176 — intervention group
Group type: COMPARATOR
Intervention: 100 ml normal saline (placebo)
Number of subjects: 80
Study 27799176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 24249722 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretic-based therapy
Number of subjects: 6083
Study 24249722 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI-based therapy
Number of subjects: 6083
Study 24249722 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting diabetes
Number of subjects: 6083
Study 24249722 — intervention group
Group type: COMPARATOR
Intervention: Newly diagnosed diabetes
Number of subjects: 6083
Study 22364647 — intervention group
Group type: EXPERIMENTAL
Intervention: ungrouped superimposed median beat (uSMB) method
Number of subjects: 38
Study 22364647 — intervention group
Group type: EXPERIMENTAL
Intervention: grouped superimposed median beat (gSMB) method
Number of subjects: 38
Study 22364647 — intervention group
Group type: EXPERIMENTAL
Intervention: both methods
Number of subjects: 38
Study 20829700 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with metoclopramide 0.5 mg/ml and diphenhydramine 0.6 mg/ml (group 4)
Number of subjects: 200
Study 20829700 — intervention group
Group type: COMPARATOR
Intervention: morphine 1 mg/ml (group 1)
Number of subjects: 200
Study 20829700 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with metoclopramide 0.5 mg/ml (group 2)
Number of subjects: 200
Study 20829700 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 1 mg/ml with diphenhydramine 0.6 mg/ml (group 3)
Number of subjects: 200
Study 18270560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg AMA1-C1/Alhydrogel
Number of subjects: 36
Study 18270560 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg AMA1-C1/Alhydrogel
Number of subjects: 36
Study 18270560 — intervention group
Group type: COMPARATOR
Intervention: Haemophilus influenzae type b Hiberix vaccine
Number of subjects: 36
Study 16181819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 51
Study 16181819 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 51
Study 12559863 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 12559863 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study 10692931 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoscopy at the end of cataract surgery
Number of subjects: 68
Study 10692931 — intervention group
Group type: COMPARATOR
Intervention: Biometric measurements
Number of subjects: 68
Study 8944106 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 2% plain
Number of subjects: 75
Study 8944106 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 1% and bupivacaine 0.5% with hyaluronidase
Number of subjects: 75
Study 2008873 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (20 g/d)
Number of subjects: 202
Study 2008873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 6605890 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentiazac suspension
Number of subjects: 50
Study 6605890 — intervention group
Group type: COMPARATOR
Intervention: Benzidamine drops
Number of subjects: 50
Study 31493105 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based exposure-focused treatment (FET)
Number of subjects: 32
Study 31493105 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 32
Study 30445176 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Changes, a weight gain prevention intervention
Number of subjects: 400
Study 30445176 — intervention group
Group type: EXPERIMENTAL
Intervention: Look AHEAD Intensive Lifestyle Intervention
Number of subjects: 400
Study 30445176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity bibliotherapy intervention
Number of subjects: 400
Study 27367916 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 122
Study 27367916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 122
Study 27367916 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching
Number of subjects: 122
Study 27367916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 26318758 — intervention group
Group type: COMPARATOR
Intervention: CNTRL (unsupplemented pasture)
Number of subjects: 24
Study 26318758 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAX‐1 (0.125% BW whole flaxseed)
Number of subjects: 24
Study 26318758 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAX‐0 (0.7% BW cracked corn)
Number of subjects: 24
Study 26318758 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAX‐2 (0.250% BW whole flaxseed)
Number of subjects: 24
Study 26318758 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem aging time (3, 14, and 56 days) with aerobic exposure (AE)
Number of subjects: 24
Study 25205641 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via the hypoglossal nerve (therapy maintenance 'ON' group)
Number of subjects: 46
Study 25205641 — intervention group
Group type: COMPARATOR
Intervention: Upper airway stimulation via the hypoglossal nerve (therapy withdrawal 'OFF' group)
Number of subjects: 46
Study 25205641 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation via the hypoglossal nerve (both groups at 18 months)
Number of subjects: 46
Study 21729466 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Fe supplementation of 65 mg/d for two months (group II)
Number of subjects: 959
Study 21729466 — intervention group
Group type: COMPARATOR
Intervention: Selective anaemia screening of high-risk women (control)
Number of subjects: 959
Study 21729466 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal anaemia screening and treatment of anaemic women (group I)
Number of subjects: 959
Study 19753635 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus-only (0.25 mg/kg)
Number of subjects: 1005
Study 19753635 — intervention group
Group type: COMPARATOR
Intervention: Abciximab bolus + infusion (12 hours)
Number of subjects: 1005
Study 19753635 — intervention group
Group type: COMPARATOR
Intervention: Not-randomized group (abciximab bolus and infusion)
Number of subjects: 1005
Study 17888214 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized administration (PC)
Number of subjects: 138
Study 17888214 — intervention group
Group type: COMPARATOR
Intervention: Interviewer administration (IA)
Number of subjects: 138
Study 15554742 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% adapalene gel
Number of subjects: 0
Study 15554742 — intervention group
Group type: COMPARATOR
Intervention: 0.025% tretinoin gel
Number of subjects: 0
Study 15554742 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tretinoin microsphere gel
Number of subjects: 0
Study 15554742 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 0
Study 15554742 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tazarotene gel (once every two days)
Number of subjects: 0
Study 15554742 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tazarotene gel (once daily)
Number of subjects: 0
Study 11442615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel sheeting (applied 48 hours after surgery)
Number of subjects: 2
Study 11442615 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative care
Number of subjects: 2
Study 11442615 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel sheeting (following scar revision procedure)
Number of subjects: 2
Study 10958249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg
Number of subjects: 12
Study 10958249 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 12
Study 10958249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg + Haloperidol 3 mg
Number of subjects: 12
Study 10958249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8032040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde inhalation challenge at 0.032 ppm
Number of subjects: 1
Study 8032040 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde inhalation challenge at up to 0.32 ppm for 10 min (second series)
Number of subjects: 1
Study 8032040 — intervention group
Group type: COMPARATOR
Intervention: Control days (unblinded workplace challenge)
Number of subjects: 1
Study 2470577 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrocortisone
Number of subjects: 13
Study 2470577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1079972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐3 DPG‐enriched previously frozen, washed, concentrated red cells (2‐3 DPG 150 percent of normal)
Number of subjects: 22
Study 1079972 — intervention group
Group type: COMPARATOR
Intervention: CPD‐stored or fresh blood (70 percent of normal 2‐3 DPG)
Number of subjects: 22
Study 29750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal catheter location (n = 24)
Number of subjects: 50
Study 29750695 — intervention group
Group type: COMPARATOR
Intervention: Distal catheter location (n = 26)
Number of subjects: 50
Study 29750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal catheter location
Number of subjects: 50
Study 29750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 27131614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy (fibrinolysis followed by transfer for PCI)
Number of subjects: 1701
Study 27131614 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI (PPCI)
Number of subjects: 1701
Study 27131614 — intervention group
Group type: COMPARATOR
Intervention: PPCI
Number of subjects: 1701
Study 24963599 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine‐assisted therapy protocol (EAT), 16-week program, 2 hours of activity per week
Number of subjects: 20
Study 24963599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 23145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual financial incentives every 4 months for 5 periods
Number of subjects: 83
Study 23145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Group financial incentives every 4 months for 5 periods
Number of subjects: 83
Study 23145846 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined financial incentives every 4 months for 5 periods
Number of subjects: 83
Study 23145846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 83
Study 21098770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography (combined transesophageal and endobronchial ultrasound) followed by surgical staging if no nodal metastases found
Number of subjects: 241
Study 21098770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography followed by surgical staging
Number of subjects: 241
Study 21098770 — intervention group
Group type: COMPARATOR
Intervention: Surgical staging
Number of subjects: 241
Study 21098770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography
Number of subjects: 241
Study 21098770 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography and surgical staging
Number of subjects: 241
Study 18482234 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mug.kg(‐1) IT fentanyl
Number of subjects: 56
Study 18482234 — intervention group
Group type: COMPARATOR
Intervention: Control group (plain 0.5% hyperbaric bupivacaine)
Number of subjects: 56
Study 16603609 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX (2%)
Number of subjects: 385
Study 16603609 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX/COL (2%/2%)
Number of subjects: 385
Study 16603609 — intervention group
Group type: COMPARATOR
Intervention: PLAC (placebo)
Number of subjects: 385
Study 16603609 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX/COL
Number of subjects: 385
Study 16603609 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX
Number of subjects: 385
Study 14561536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesigyna (50 mg norethisterone enanthate and 5 mg estradiol valerate)
Number of subjects: 378
Study 14561536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem (25 mg medroxyprogesterone acetate and 5 mg estradiol cypionate)
Number of subjects: 378
Study 14561536 — intervention group
Group type: COMPARATOR
Intervention: Ortho-Novum 1/35 (norethisterone 1 mg and ethinyl estradiol 35 microg)
Number of subjects: 378
Study 10826048 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative technique (ART)
Number of subjects: 0
Study 10826048 — intervention group
Group type: COMPARATOR
Intervention: Conventional restorative technique
Number of subjects: 0
Study 8778550 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR) at a workload corresponding to 32% of maximal aerobic power
Number of subjects: 10
Study 8778550 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study 1898892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (gonadotropin followed by pulsatile GnRH)
Number of subjects: 8
Study 1898892 — intervention group
Group type: COMPARATOR
Intervention: Pure exogenous follicle-stimulating hormone alone
Number of subjects: 8
Study 6227542 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprosalic Solution (0.64 mg betamethasone‐dipropionate plus 20 mg salicylic acid)
Number of subjects: 100
Study 6227542 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate solution (0.64 mg)
Number of subjects: 100
Study 29920834 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282
Study 29920834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise as an adjuvant treatment in myopathies
Number of subjects: 0
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Number of subjects: 0
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (general)
Number of subjects: 0
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (specific modes)
Number of subjects: 0
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (in dysferlinopathy)
Number of subjects: 0
Study 30036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeletons and antigravity trainers
Number of subjects: 0
Study 26756107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin
Number of subjects: 91
Study 26756107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 25514273 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 35
Study 25514273 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 35
Study 25514273 — intervention group
Group type: COMPARATOR
Intervention: Shoes
Number of subjects: 35
Study 22248605 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC) with sphincterotome (S)
Number of subjects: 400
Study 22248605 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (C)
Number of subjects: 400
Study 19464824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment FDG-PET
Number of subjects: 129
Study 19464824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FDG-PET)
Number of subjects: 129
Study 17148938 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment for 6 weeks
Number of subjects: 14
Study 17148938 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 14
Study 15886473 — intervention group
Group type: EXPERIMENTAL
Intervention: HA in combination with DOX (30-60 mg/m2)
Number of subjects: 30
Study 15886473 — intervention group
Group type: EXPERIMENTAL
Intervention: HA in combination with 5-FU (cumulative dose of 1,350-2,250 mg/m2 per cycle)
Number of subjects: 30
Study 15886473 — intervention group
Group type: COMPARATOR
Intervention: HA/chemotherapy
Number of subjects: 30
Study 15886473 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 30
Study 12070557 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg/day orally)
Number of subjects: 0
Study 12070557 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30 mg/day orally)
Number of subjects: 0
Study 10049988 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV (pressure support ventilation) during CPT
Number of subjects: 16
Study 10049988 — intervention group
Group type: COMPARATOR
Intervention: Control session (no PSV)
Number of subjects: 16
Study 7596622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (titrated from 0.1 to 0.3 mg/day)
Number of subjects: 41
Study 7596622 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 41
Study 2193993 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25% eyedrops
Number of subjects: 16
Study 2193993 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 16
Study 369298 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 0
Study 369298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 369298 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 30954691 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg of 3% saline (hypertonic group)
Number of subjects: 65
Study 30954691 — intervention group
Group type: COMPARATOR
Intervention: 10 mL/kg of 0.9% saline (isotonic group)
Number of subjects: 65
Study 27737489 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Combined Training Group (SCG)
Number of subjects: 54
Study 27737489 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Combined Training Group (ICG)
Number of subjects: 54
Study 27737489 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 54
Study 26141464 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin before surgery
Number of subjects: 142
Study 26141464 — intervention group
Group type: COMPARATOR
Intervention: Postoperative eradication regimen: rabeprazole, amoxicillin, and clarithromycin after postoperative day 8
Number of subjects: 142
Study 23625100 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo holding (skin-to-skin between mother's breasts)
Number of subjects: 87
Study 23625100 — intervention group
Group type: EXPERIMENTAL
Intervention: Blanket holding (held in mother's arms)
Number of subjects: 87
Study 23625100 — intervention group
Group type: COMPARATOR
Intervention: Control (no holding restrictions)
Number of subjects: 87
Study 21276583 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces in temporal bisection task
Number of subjects: 0
Study 21276583 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces in verbal estimation task
Number of subjects: 0
Study 21276583 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces in production task
Number of subjects: 0
Study 21276583 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces in temporal bisection task
Number of subjects: 0
Study 21276583 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces in verbal estimation task
Number of subjects: 0